Does the media refer more to INBX or ARCT?

In the previous week, Inhibrx Biosciences had 12 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 17 mentions for Inhibrx Biosciences and 5 mentions for Arcturus Therapeutics. Inhibrx Biosciences' average media sentiment score of 1.23 beat Arcturus Therapeutics' score of 0.95 indicating that Inhibrx Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcturus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ARCT or NVAX?

In the previous week, Novavax had 6 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 11 mentions for Novavax and 5 mentions for Arcturus Therapeutics. Arcturus Therapeutics' average media sentiment score of 0.95 beat Novavax's score of 0.41 indicating that Arcturus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novavax 2 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ARCT or ORIC?

In the previous week, Arcturus Therapeutics had 1 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 5 mentions for Arcturus Therapeutics and 4 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 1.41 beat Arcturus Therapeutics' score of 0.95 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oric Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ARCT or AVBP?

In the previous week, ArriVent BioPharma had 1 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 6 mentions for ArriVent BioPharma and 5 mentions for Arcturus Therapeutics. Arcturus Therapeutics' average media sentiment score of 0.95 beat ArriVent BioPharma's score of 0.43 indicating that Arcturus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ArriVent BioPharma 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer CGEM or ARCT?

In the previous week, Cullinan Therapeutics had 7 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 12 mentions for Cullinan Therapeutics and 5 mentions for Arcturus Therapeutics. Cullinan Therapeutics' average media sentiment score of 1.17 beat Arcturus Therapeutics' score of 0.95 indicating that Cullinan Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcturus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Arcturus Therapeutics (ARCT) Competitors

$15.96 +0.13 (+0.80%)

As of 12:18 PM Eastern

Compare

ARCT vs. INBX, NVAX, ORIC, AVBP, and CGEM

Should you buy Arcturus Therapeutics stock or one of its competitors? Arcturus Therapeutics's main competitors and comparable companies include Inhibrx Biosciences (INBX), Novavax (NVAX), Oric Pharmaceuticals (ORIC), ArriVent BioPharma (AVBP), and Cullinan Therapeutics (CGEM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Arcturus Therapeutics compare to Inhibrx Biosciences?

Inhibrx Biosciences (NASDAQ:INBX) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Inhibrx Biosciences has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -317.62%. Arcturus Therapeutics' return on equity of -46.54% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-83.48%
Arcturus Therapeutics	-317.62%	-46.54%	-36.46%

In the previous week, Inhibrx Biosciences had 12 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 17 mentions for Inhibrx Biosciences and 5 mentions for Arcturus Therapeutics. Inhibrx Biosciences' average media sentiment score of 1.23 beat Arcturus Therapeutics' score of 0.95 indicating that Inhibrx Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcturus Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inhibrx Biosciences has a beta of 3.51, meaning that its share price is 251% more volatile than the broader market. Comparatively, Arcturus Therapeutics has a beta of 2.39, meaning that its share price is 139% more volatile than the broader market.

Arcturus Therapeutics has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	N/A	N/A	-$140.05M	-$8.88	N/A
Arcturus Therapeutics	$82.03M	5.47	-$65.78M	-$3.31	N/A

Inhibrx Biosciences presently has a consensus price target of $197.50, suggesting a potential upside of 56.60%. Arcturus Therapeutics has a consensus price target of $20.00, suggesting a potential upside of 26.57%. Given Inhibrx Biosciences' higher probable upside, equities research analysts clearly believe Inhibrx Biosciences is more favorable than Arcturus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60

82.5% of Inhibrx Biosciences shares are held by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are held by institutional investors. 18.3% of Inhibrx Biosciences shares are held by company insiders. Comparatively, 17.8% of Arcturus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Arcturus Therapeutics beats Inhibrx Biosciences on 9 of the 15 factors compared between the two stocks.

How does Arcturus Therapeutics compare to Novavax?

Arcturus Therapeutics (NASDAQ:ARCT) and Novavax (NASDAQ:NVAX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

Novavax has a net margin of -59.87% compared to Arcturus Therapeutics' net margin of -317.62%. Novavax's return on equity of -14.82% beat Arcturus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-317.62%	-46.54%	-36.46%
Novavax	-59.87%	-14.82%	-13.35%

Arcturus Therapeutics has a beta of 2.39, suggesting that its share price is 139% more volatile than the broader market. Comparatively, Novavax has a beta of 2.46, suggesting that its share price is 146% more volatile than the broader market.

Arcturus Therapeutics currently has a consensus target price of $20.00, indicating a potential upside of 26.57%. Novavax has a consensus target price of $14.00, indicating a potential upside of 56.08%. Given Novavax's higher probable upside, analysts plainly believe Novavax is more favorable than Arcturus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60
Novavax	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Novavax has higher revenue and earnings than Arcturus Therapeutics. Novavax is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$82.03M	5.47	-$65.78M	-$3.31	N/A
Novavax	$1.12B	1.32	$440.30M	-$1.52	N/A

In the previous week, Novavax had 6 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 11 mentions for Novavax and 5 mentions for Arcturus Therapeutics. Arcturus Therapeutics' average media sentiment score of 0.95 beat Novavax's score of 0.41 indicating that Arcturus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcturus Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novavax	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 17.8% of Arcturus Therapeutics shares are owned by company insiders. Comparatively, 1.6% of Novavax shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Novavax beats Arcturus Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Arcturus Therapeutics compare to Oric Pharmaceuticals?

Arcturus Therapeutics (NASDAQ:ARCT) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

In the previous week, Arcturus Therapeutics had 1 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 5 mentions for Arcturus Therapeutics and 4 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 1.41 beat Arcturus Therapeutics' score of 0.95 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcturus Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oric Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcturus Therapeutics has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$82.03M	5.47	-$65.78M	-$3.31	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A

Oric Pharmaceuticals has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -317.62%. Oric Pharmaceuticals' return on equity of -35.35% beat Arcturus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-317.62%	-46.54%	-36.46%
Oric Pharmaceuticals	N/A	-35.35%	-33.39%

Arcturus Therapeutics presently has a consensus target price of $20.00, indicating a potential upside of 26.57%. Oric Pharmaceuticals has a consensus target price of $19.45, indicating a potential upside of 38.37%. Given Oric Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Oric Pharmaceuticals is more favorable than Arcturus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Arcturus Therapeutics has a beta of 2.39, meaning that its share price is 139% more volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market.

94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are owned by institutional investors. 17.8% of Arcturus Therapeutics shares are owned by insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Oric Pharmaceuticals beats Arcturus Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Arcturus Therapeutics compare to ArriVent BioPharma?

Arcturus Therapeutics (NASDAQ:ARCT) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Arcturus Therapeutics has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$82.03M	5.47	-$65.78M	-$3.31	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.62	N/A

94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 17.8% of Arcturus Therapeutics shares are owned by company insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ArriVent BioPharma has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -317.62%. Arcturus Therapeutics' return on equity of -46.54% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-317.62%	-46.54%	-36.46%
ArriVent BioPharma	N/A	-50.26%	-46.66%

In the previous week, ArriVent BioPharma had 1 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 6 mentions for ArriVent BioPharma and 5 mentions for Arcturus Therapeutics. Arcturus Therapeutics' average media sentiment score of 0.95 beat ArriVent BioPharma's score of 0.43 indicating that Arcturus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcturus Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ArriVent BioPharma	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Arcturus Therapeutics presently has a consensus price target of $20.00, suggesting a potential upside of 26.57%. ArriVent BioPharma has a consensus price target of $44.86, suggesting a potential upside of 44.52%. Given ArriVent BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe ArriVent BioPharma is more favorable than Arcturus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Arcturus Therapeutics has a beta of 2.39, suggesting that its share price is 139% more volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market.

Summary

Arcturus Therapeutics beats ArriVent BioPharma on 11 of the 16 factors compared between the two stocks.

How does Arcturus Therapeutics compare to Cullinan Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

86.3% of Cullinan Therapeutics shares are held by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are held by institutional investors. 8.6% of Cullinan Therapeutics shares are held by company insiders. Comparatively, 17.8% of Arcturus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Cullinan Therapeutics has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -317.62%. Arcturus Therapeutics' return on equity of -46.54% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-52.89%	-48.18%
Arcturus Therapeutics	-317.62%	-46.54%	-36.46%

Cullinan Therapeutics currently has a consensus price target of $32.86, indicating a potential upside of 45.84%. Arcturus Therapeutics has a consensus price target of $20.00, indicating a potential upside of 26.57%. Given Cullinan Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Cullinan Therapeutics is more favorable than Arcturus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60

Arcturus Therapeutics has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A
Arcturus Therapeutics	$82.03M	5.47	-$65.78M	-$3.31	N/A

Cullinan Therapeutics has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market. Comparatively, Arcturus Therapeutics has a beta of 2.39, meaning that its share price is 139% more volatile than the broader market.

In the previous week, Cullinan Therapeutics had 7 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 12 mentions for Cullinan Therapeutics and 5 mentions for Arcturus Therapeutics. Cullinan Therapeutics' average media sentiment score of 1.17 beat Arcturus Therapeutics' score of 0.95 indicating that Cullinan Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcturus Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Arcturus Therapeutics beats Cullinan Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Arcturus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARCT vs. The Competition

Export

Metric	Arcturus Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$449.21M	$4.01B	$7.24B	$12.89B
Dividend Yield	N/A	3.63%	2.54%	11.02%
P/E Ratio	-4.78	11.83	272.56	24.24
Price / Sales	5.47	1,298.90	605.16	79.37
Price / Cash	N/A	108.37	79.89	53.65
Price / Book	2.62	16.64	13.09	6.28
Net Income	-$65.78M	-$22.76M	$3.46B	$347.85M
7 Day Performance	43.78%	3.71%	2.17%	1.52%
1 Month Performance	174.32%	12.07%	8.39%	4.76%
1 Year Performance	-8.61%	58.71%	26.43%	17.04%

Arcturus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARCT Arcturus Therapeutics	2.7424 of 5 stars	$15.96 +0.8%	$20.00 +25.3%	-9.7%	$454.04M	$82.03M	N/A	180	Positive News
INBX Inhibrx Biosciences	2.8507 of 5 stars	$104.94 +1.3%	$197.50 +88.2%	+383.6%	$1.53B	$1.30M	N/A	166	Trending News Analyst Forecast Analyst Revision
NVAX Novavax	1.697 of 5 stars	$8.86 -0.9%	$14.00 +58.0%	+22.8%	$1.47B	$413.80M	N/A	1,990	Options Volume
ORIC Oric Pharmaceuticals	2.9871 of 5 stars	$13.46 -5.2%	$19.45 +44.5%	+41.2%	$1.47B	N/A	N/A	80	Positive News
AVBP ArriVent BioPharma	2.2109 of 5 stars	$28.26 -3.0%	$44.86 +58.7%	+59.0%	$1.44B	N/A	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARCT) was last updated on 8/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arcturus Therapeutics (ARCT) Competitors

ARCT vs. INBX, NVAX, ORIC, AVBP, and CGEM

How does Arcturus Therapeutics compare to Inhibrx Biosciences?

Summary

How does Arcturus Therapeutics compare to Novavax?

Summary

How does Arcturus Therapeutics compare to Oric Pharmaceuticals?

Summary

How does Arcturus Therapeutics compare to ArriVent BioPharma?

Summary

How does Arcturus Therapeutics compare to Cullinan Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARCT vs. The Competition

Arcturus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arcturus Therapeutics (ARCT) Competitors

ARCT vs. INBX, NVAX, ORIC, AVBP, and CGEM

How does Arcturus Therapeutics compare to Inhibrx Biosciences?

Is INBX or ARCT more profitable?

Does the media refer more to INBX or ARCT?

Which has more risk and volatility, INBX or ARCT?

Which has stronger valuation and earnings, INBX or ARCT?

Do analysts recommend INBX or ARCT?

Do institutionals & insiders hold more shares of INBX or ARCT?

Summary

How does Arcturus Therapeutics compare to Novavax?

Is ARCT or NVAX more profitable?

Which has more risk and volatility, ARCT or NVAX?

Do analysts rate ARCT or NVAX?

Which has stronger earnings and valuation, ARCT or NVAX?

Does the media prefer ARCT or NVAX?

Do insiders and institutionals have more ownership in ARCT or NVAX?

Summary

How does Arcturus Therapeutics compare to Oric Pharmaceuticals?

Does the media refer more to ARCT or ORIC?

Which has higher earnings and valuation, ARCT or ORIC?

Is ARCT or ORIC more profitable?

Do analysts prefer ARCT or ORIC?

Which has more volatility and risk, ARCT or ORIC?

Do institutionals and insiders believe in ARCT or ORIC?

Summary

How does Arcturus Therapeutics compare to ArriVent BioPharma?

Which has higher earnings & valuation, ARCT or AVBP?

Do insiders and institutionals hold more shares of ARCT or AVBP?

Is ARCT or AVBP more profitable?

Does the media refer more to ARCT or AVBP?

Do analysts recommend ARCT or AVBP?

Which has more risk and volatility, ARCT or AVBP?

Summary

How does Arcturus Therapeutics compare to Cullinan Therapeutics?

Do institutionals and insiders believe in CGEM or ARCT?

Is CGEM or ARCT more profitable?

Do analysts prefer CGEM or ARCT?

Which has stronger earnings & valuation, CGEM or ARCT?

Which has more risk & volatility, CGEM or ARCT?

Does the media prefer CGEM or ARCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARCT vs. The Competition

Arcturus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools